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Abstract
Background: Human immunodeficiency virus (HIV) infection is the strongest risk factor for developing tuberculosis and has
fuelled its resurgence, especially in sub-Saharan Africa. In 2010, there were an estimated 1.1 million incident cases of
tuberculosis among the 34 million people living with HIV worldwide. Antiretroviral therapy has substantial potential to
prevent HIV-associated tuberculosis. We conducted a systematic review of studies that analysed the impact of antiretroviral
therapy on the incidence of tuberculosis in adults with HIV infection.
Methods and Findings: PubMed, Embase, African Index Medicus, LILACS, and clinical trial registries were systematically
searched. Randomised controlled trials, prospective cohort studies, and retrospective cohort studies were included if they
compared tuberculosis incidence by antiretroviral therapy status in HIV-infected adults for a median of over 6 mo in
developing countries. For the meta-analyses there were four categories based on CD4 counts at antiretroviral therapy
initiation: (1) less than 200 cells/ml, (2) 200 to 350 cells/ml, (3) greater than 350 cells/ml, and (4) any CD4 count. Eleven studies
met the inclusion criteria. Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis in all
baseline CD4 count categories: (1) less than 200 cells/ml (hazard ratio [HR] 0.16, 95% confidence interval [CI] 0.07 to 0.36), (2)
200 to 350 cells/ml (HR 0.34, 95% CI 0.19 to 0.60), (3) greater than 350 cells/ml (HR 0.43, 95% CI 0.30 to 0.63), and (4) any CD4
count (HR 0.35, 95% CI 0.28 to 0.44). There was no evidence of hazard ratio modification with respect to baseline CD4 count
category (p= 0.20).
Conclusions: Antiretroviral therapy is strongly associated with a reduction in the incidence of tuberculosis across all CD4
count strata. Earlier initiation of antiretroviral therapy may be a key component of global and national strategies to control
the HIV-associated tuberculosis syndemic.
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Introduction
Tuberculosis and human immunodeficiency virus (HIV) are
major threats to global public health. HIV infection is the strongest
risk factor for tuberculosis and has fuelled its resurgence [1]. In
2010 there were an estimated 1.1 million incident cases of
tuberculosis among the 34 million people living with HIV
worldwide; 900,000 of these cases were among the 22.9 million
Africans living with HIV [2,3]. The 350,000 deaths among
incident HIV-positive tuberculosis cases comprised 19% of all
HIV-related deaths [2] and 24% of all tuberculosis deaths globally
[3].
As part of the Millennium Development Goals, all 192 United
Nations member states agreed to halt and decrease the annual
mortality, incidence, and prevalence of tuberculosis and to
increase the proportion of tuberculosis cases detected and cured
under the DOTS strategy by 2015 [4]. The World Health
Organization (WHO) and the Stop TB Partnership have endorsed
the Millennium Development Goal targets and also aim to reduce
the global annual incidence of active tuberculosis to less than one
case per million population by 2050 [5]. While latest estimates
indicate that the world is on track to achieve the Millennium
Development Goal targets [3], achieving elimination will require a
shift in strategy [6–8].
The DOTS strategy was largely developed in the pre-HIV era,
and its implementation between 1995 and 2010 helped success-
fully treat 46 million people with tuberculosis and save 6.8 million
lives [3]. While the DOTS strategy is essential for people with and
without HIV, it is unlikely to reduce the incidence and prevalence
of tuberculosis in countries where HIV is highly prevalent [9].
Given the importance of HIV as a driver of the tuberculosis
epidemic in many regions, especially in Africa, where approxi-
mately 40% of incident tuberculosis cases in 2010 were associated
with HIV [3], WHO recommends a range of collaborative
activities through which HIV and tuberculosis programmes can
address HIV-associated tuberculosis [10]. These include the Three
I’s for HIV/TB: intensified tuberculosis case-finding [11],
isoniazid preventive therapy [11], and tuberculosis infection
control [12]. Unfortunately only 178,144 people, a small fraction
of the millions eligible, received isoniazid preventive therapy in
2010 [3]. The barriers contributing to this low coverage of
isoniazid preventive therapy are complex and underscore the need
for complementary interventions to prevent tuberculosis in adults
with HIV [1,11,13].
In 2009, WHO recommended antiretroviral therapy for all
adults with CD4 counts less than 350 cells/ml and for all
tuberculosis patients irrespective of CD4 count [14]. In more
recent years, accumulating evidence has pointed towards the
potential of antiretroviral therapy scale-up to further contribute to
control of the HIV-associated tuberculosis syndemic [15,16,17].
However, the evidence regarding antiretroviral therapy’s preven-
tive impact on tuberculosis has not undergone formal systematic
review or synthesis. The objective of this study was to systemat-
ically review the effect of antiretroviral therapy on incident
tuberculosis in developing countries across a range of CD4 cell
count strata.
Methods
Conduct of Systematic Review
This systematic review was conducted in accordance with the
PRISMA (Preferred Reporting Items for Systematic Review and
Meta-Analyses) statement (Text S1) [18]. The investigators wrote a
protocol and registered it with the International Prospective
Register of Systematic Reviews (identification number:
CRD42011001209) in March 2011 [19]. PubMed and Embase
were systematically searched without language, publication, or
date restrictions in August 2011, while African Index Medicus and
LILACS (Latin American and Caribbean Health Science Liter-
ature Database) were systematically searched without language,
publication, or date restrictions in February 2012.
Search Strategy, Selection Criteria, and Data Extraction
The search strategies (Table S1) were designed with a librarian
to identify studies reporting on the effect of antiretroviral therapy
in preventing HIV-associated tuberculosis. Per recommendations
from the PRISMA Group, eligibility criteria were based on key
study characteristics: population, intervention, comparator, out-
come, design, and length of follow-up [18]. Specifically, studies
were included when (1) the study population was composed of
adults ($13 y) with HIV; (2) the intervention was antiretroviral
therapy (defined as three or more antiretroviral drugs used in
combination); (3) the comparator was no antiretroviral drugs; (4)
the outcome was an incident case of tuberculosis; (5) the study
design was a randomised trial, prospective cohort study, or
retrospective cohort study; and (6) participants were followed for
more than 6 mo (since viral suppression, immune recovery, and
associated tuberculosis risk reduction is a time-dependent process
[20–24] and tuberculosis rates during early antiretroviral therapy
depend highly upon the intensity of screening for prevalent
tuberculosis prior to antiretroviral therapy initiation [25]). The
WHO International Clinical Trials Registry Platform, the
Cochrane Central Register of Controlled Trials, the International
Standard Randomised Controlled Trial Number Register, and
ClinicalTrials.gov were searched for future and ongoing studies
using the terms ‘‘antiretroviral’’ and ‘‘tuberculosis’’. Experts in the
field were also contacted to identify unpublished research or
ongoing studies.
Tuberculosis transmission is complex and is influenced by
biological, social, and economic factors [26]. Data from 134
countries indicate that development, measured by the Human
Development Index, correlates with national tuberculosis inci-
dence [27]. The Human Development Index is a composite
national score of health (life expectancy at birth), education
(expected years of schooling), and living standards (per capita gross
national income) [28]. The Human Development Index catego-
rises developed countries as those scoring in the top quartile and
developing countries as those scoring below the top quartile [28].
Since developed countries collectively contributed less than 0.5%
of all HIV-positive tuberculosis cases globally (Table S2), the scope
of this systematic review was limited to developing countries to
maximise the generalisability of the meta-analyses to countries
facing the highest burden of HIV-associated tuberculosis.
Two of the investigators, A. B. S. and D. S., independently
screened abstracts of all retrieved articles from PubMed and
Embase and then matched the full texts of all articles selected
during screening against the inclusion criteria. A. B. S. and R. M.
G. conducted this same process for the African Index Medicus and
LILACS databases. Disagreements on which articles met the
inclusion criteria were resolved by discussion. Articles meeting
inclusion criteria were included in the review (Figure 1). A. B. S.
and J. d. A. completed the data extraction using a standardised
spreadsheet that collected information on the first author, year of
publication, methods and design, study population, intervention
and control, duration of follow-up, inclusion and exclusion criteria,
outcomes, and losses to follow-up.
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Quality Assessment
Per recommendations from the Cochrane Collaboration [29],
the Newcastle-Ottawa quality assessment scale was used to assess
bias in studies included in this review [30]. This scale rates
studies on three sources of bias based on eight criteria. Each
criterion is worth one point except confounding, which is worth
two points. Selection bias was assessed using four criteria: (1)
representativeness of the cohort on antiretroviral therapy to the
average adult on antiretroviral therapy in the community from
which study participants were drawn, (2) representativeness of
the cohort off antiretroviral therapy to the cohort on antiretro-
viral therapy, (3) ascertainment of antiretroviral therapy use, and
(4) demonstration that prevalent tuberculosis was not present at
the start of follow-up. To judge whether appropriate methods
were used to address confounding, adjustment for baseline CD4
count was used for studies not reporting analyses in CD4 strata.
Since a low body mass index is a key risk factor for developing
tuberculosis in adults, irrespective of HIV status [8,21,31–34],
adjustment for body mass index was used to judge whether
appropriate methods were used to address confounding for
analyses within CD4 strata. Measurement bias was assessed with
three criteria: (1) microbiological (i.e., culture or acid-fast bacilli
smear) confirmation of tuberculosis cases, (2) adequate follow-up
to detect antiretroviral therapy’s long-term preventive effect on
tuberculosis (i.e., median follow-up of at least 1 y [20–24]), and
(3) #30% of participants lost to follow-up during the study.
Based on these criteria, studies were scored out of 100%. For this
systematic review, studies scoring $67% were arbitrarily
considered high methodological quality, those scoring 34%–
66% were arbitrarily considered moderate methodological
quality, and those #33% were arbitrarily considered low
methodological quality.
Per recommendations from the Cochrane Collaboration [29],
the Collaboration’s Risk of Bias tool was used to assess bias in
randomised trials meeting eligibility criteria. This tool rates studies
on four sources of bias based on six criteria: (1) adequate sequence
generation to gauge selection bias; (2) allocation concealment to
gauge selection bias; (3) blinding of participants, personnel, and
outcome assessors to gauge performance and detection bias; (4)
incomplete outcome data to gauge attrition bias; (5) selective
reporting to gauge reporting bias; and (6) a criterion for other
forms of bias. Based on these criteria, trials were scored out of
100%.
Statistical Analyses
Past WHO guidelines have used a CD4 threshold of 200 cells/
ml [35] and 350 cells/ml [14] for initiation of antiretroviral therapy
in asymptomatic adults. Given that there is considerable hetero-
geneity among different populations regarding CD4 counts
directly after seroconversion and the subsequent rate of CD4
decline, the need for multiple strata above 350 cells/ml is
population-specific [36–38]. Therefore, four categories based on
CD4 at antiretroviral therapy initiation were used for the
analytical component of this review: less than 200 cells/ml, 200
to 350 cells/ml, greater than 350 cells/ml, and any CD4 count. A
funnel plot with the effect measures on the x-axis and standard
error of the log for the effect measures on the y-axis was created to
assess publication bias, and the Egger and Begg tests were used to
test the funnel plot’s symmetry. Since studies were similar enough
to combine, meta-analyses were performed and statistical hetero-
geneity was assessed. Effect measures were entered as the natural
log of the effect measure, and standard error as the natural log of
(95% upper limit495% lower limit)43.92 [39]. Fixed-effects
models assume that the magnitude and direction of an interven-
tion’s effect is identical across studies and that observed differences
among study results are due solely to chance [29]. Random-effects
models assume that the magnitude and direction of an interven-
tion’s effect is not identical across studies but follows a distribution
[29]. Since it is possible that the magnitude and direction of
antiretroviral therapy’s preventive impact on tuberculosis could
differ for reasons other than chance, random-effects models were
used for all meta-analyses. x and t statistics require the number of
events in each study arm to assess heterogeneity in the magnitude
of effect across studies. Since these data were not available for all
studies meeting inclusion criteria, I2 statistics were used to measure
heterogeneity [40]. I2 values near 25% indicate low heterogeneity,
values near 50% indicate moderate heterogeneity, and those
above 75% indicate high heterogeneity [41]. The x2 test, against
the null hypothesis that there is no difference in the hazard ratio
(HR) with respect to baseline CD4 count category, was used to test
for hazard ratio modification. STATA version 10.0 was used for
all analyses.
Figure 1. Flow of information through different phases of the
review.
doi:10.1371/journal.pmed.1001270.g001
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Results
Search Results
Eleven studies met the inclusion criteria for this systematic
review (Tables 1 and 2) [42–52]. Four of these studies were from
sub-Saharan Africa [42,44,46,49], four were from South America
[45,47,48,50], one was from the Caribbean [51], one was from
Asia [52], and one was from a combination of regions in sub-
Saharan Africa, South America, and Asia [43]. Two studies
reported effect estimates for baseline CD4 counts less than 200
cells/ml [42,47], four studies reported effect estimates for baseline
CD4 counts from 200 to 350 cells/ml [42,45,47,51], and three
studies reported effect estimates for baseline CD4 counts greater
than 350 cells/ml [42,43,45] (Figure 2). One ongoing randomised
study was identified in the Cochrane Central Register of
Controlled Trials [53], three additional ongoing trials were
identified in ClinicalTrials.gov [54–56], while no additional
studies were found in the International Standard Randomised
Controlled Trial Number Register or the WHO International
Clinical Trials Registry Platform. Results on antiretroviral
therapy’s preventive impact on tuberculosis are not yet available
from the ongoing trials [53–56].
Quality Assessment
The assessment of bias indicated that four studies were of high
methodological quality [43,48,49,51], five studies were of moder-
ate methodological quality [42,44,45,47,50], and two studies were
of low methodological quality [46,52] (Table 3). There appeared
to be limited bias in the three randomised controlled trials
identified [43,49,51] (Table 4).
Meta-Analyses
A meta-analysis of all eleven studies meeting inclusion criteria
found that antiretroviral therapy is strongly associated with a
reduction in tuberculosis incidence across all baseline CD4 counts
(HR 0.35, 95% confidence interval [CI] 0.28 to 0.44; p-value for
effect ,0.001; p-value for heterogeneity = 0.151). Inspection of the
funnel plot (Figure S1) suggested possible publication bias (Begg
test p=0.12; Egger test p=0.02).
Two studies reported on participants with baseline CD4 counts
less than 200 cells/ml. Badri et al. [42] (adjusted incidence rate
ratio [IRR] 0.18, 95% CI 0.07 to 0.47) and Lannoy et al. [47]
(IRR 0.11, 95% CI 0.02 to 0.52; Text S2) reported that
antiretroviral therapy was associated with a reduction in tubercu-
losis incidence. A meta-analysis of these two studies found that
antiretroviral therapy is strongly associated with a reduction in
tuberculosis incidence in adults with baseline CD4 counts less than
200 cells/ml (HR 0.16, 95% CI 0.07 to 0.36; p-value for effect
,0.001; p-value for heterogeneity = 0.609).
Four studies reported on participants with baseline CD4 counts
from 200 to 350 cells/ml. Badri et al. [42] (adjusted IRR 0.12, 95%
CI 0.03 to 0.53), Lannoy et al. [47] (adjusted HR 0.10, 95% CI
0.02 to 0.45), Golub et al. [45] (adjusted HR 0.46, 95% CI 0.33 to
0.63), and Severe et al. [51] (HR 0.50, 95% CI 0.29 to 0.83)
reported that antiretroviral therapy was associated with a
reduction in tuberculosis incidence. The meta-analysis of these
four studies found that antiretroviral therapy is strongly associated
with a reduction in tuberculosis incidence in adults with baseline
CD4 counts from 200 to 350 cells/ml (HR 0.34, 95% CI 0.19 to
0.60; p-value for effect ,0.001; p-value for heterogeneity = 0.069).
Three studies reported on participants with baseline CD4
counts above 350 cells/ml. Cohen et al. [43] (IRR 0.51, 95% CI
0.28 to 0.91; Text S2), Badri et al. [42] (adjusted IRR 0.36, 95%
CI 0.10 to 1.74), and Golub et al. [45] (adjusted HR 0.39, 95% CI
0.23 to 0.66) reported that antiretroviral therapy was associated
with a reduction in tuberculosis incidence, although Badri’s
estimate lacked statistical significance. The meta-analysis of these
three studies indicated that antiretroviral therapy is strongly
associated with a reduction in tuberculosis incidence in adults with
CD4 counts above 350 cells/ml (HR 0.43, 95% CI 0.30 to 0.63; p-
value for effect ,0.001; p-value for heterogeneity = 0.774).
Visual inspection of the hazard ratios and confidence intervals
for the three CD4 categories suggested a possible gradient in
antiretroviral therapy’s effect in relation to baseline CD4 count
(Figure 3); however, there was no evidence of hazard ratio
modification with respect to baseline CD4 count category using
the x2 test (p=0.20).
Discussion
This systematic review indicates that antiretroviral therapy is
strongly associated with a reduction in tuberculosis incidence in
adults with CD4 counts (1) less than 200 cells/ml (HR 0.16, 95%
CI 0.07 to 0.36), (2) from 200 to 350 cells/ml (HR 0.34, 95% CI
0.19 to 0.60), (3) greater than 350 cells/ml (HR 0.43, 95% CI 0.30
to 0.63), and (4) at any level (HR 0.35, 95% CI 0.28 to 0.45). This
study was a rigorous systematic literature review that focused
exclusively on studies from developing countries and included very
recent studies that provided data on adults with high baseline CD4
cell counts. These factors enabled what is, to our knowledge, the
first ever estimate of antiretroviral therapy impact stratified by
baseline CD4 category. The finding that antiretroviral therapy is
strongly associated with a reduction in tuberculosis incidence
across all CD4 counts is consistent with an earlier meta-analysis
that included studies from developed and developing countries
[13]. That meta-analysis, the meta-analyses reported here, and a
previous comparative analysis of data from developed and
developing countries [57] support the conclusion that tuberculosis
risk reduction is similar regardless of country.
Nine of the 11 studies meeting the inclusion criteria were of
moderate or high methodological quality (Tables 3 and 4).
However, there were some methodological limitations that need to
be considered when evaluating the strong association between
antiretroviral therapy and the reduction of tuberculosis incidence.
Since diagnostic capabilities differed by country and study site,
some studies did not microbiologically confirm tuberculosis cases,
which could induce measurement bias. Moreover, one of the
studies found that earlier antiretroviral therapy was associated with
a decrease only in extrapulmonary tuberculosis, while the others
did not make a distinction between pulmonary and extrapulmo-
nary disease [43]. Stratifying by disease site in future studies may
be useful in explaining the contribution of antiretroviral therapy in
preventing different types of tuberculosis. Since tuberculosis
incidence rates during early antiretroviral therapy depend highly
upon the efficiency of tuberculosis screening prior to antiretroviral
therapy initiation [25], prevalent cases of tuberculosis are often
unmasked soon after antiretroviral therapy initiation [20,58].
Despite efforts to screen for prevalent tuberculosis at study
baseline, it is difficult for investigators to establish definitively
whether tuberculosis cases that develop soon after antiretroviral
therapy initiation are truly incident cases. This uncertainly could
introduce measurement bias into studies with a short period of
follow-up. Furthermore, the complexity and expense of conduct-
ing randomised controlled trials means that most of our data were
derived from observational studies. Although our analyses
included data from randomised controlled trials, the potential
for unmeasured confounding in prospective and retrospective
cohort studies makes attempts to reliably establish causal effect
Prevention of Tuberculosis in Adults with HIV
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more difficult. For example, in some studies there is potential for
unmeasured confounding due to isoniazid preventive therapy
(Table 2). Nonetheless, our finding that there is no hazard ratio
modification with respect to baseline CD4 count is consistent with
the randomised controlled trials, in which the reduction in
tuberculosis incidence when initiating antiretroviral therapy at
200 to 350 cells/ml (HR 0.50, 95% CI 0.28 to 0.83) [51] was
nearly identical to the reduction in tuberculosis incidence when
initiating antiretroviral therapy above 350 cells/ml (IRR 0.51, 95%
CI 0.28 to 0.91) [43]. These randomised controlled trial stratum
estimates were also very similar to the 63% and 57% reductions
obtained in the meta-analyses for the categories 200–350 cells/ml
and greater than 350 cells/ml, respectively.
The meta-analyses may have limitations in the statistical
methodology used. Since laboratory capabilities differed by
country and study site, some of the studies did not adjust for
baseline CD4 count, body mass index, smoking, and/or diabetes,
which could confound results. Both incidence rate ratios and
hazard ratios calculate events over person-time at risk; however,
they rely on different methodologies depending on the nature of
the data that are collected [59]. Given similarities in study
methods (Table 2), the meta-analyses in this systematic review
combined hazard ratios and incidence rate ratios from randomised
controlled trials and cohort studies. A meta-regression of all studies
included in the meta-analysis for all CD4 counts found that the
type of effect measure (i.e., hazard ratio or incidence rate ratio) did
not explain the heterogeneity in the magnitude of effect (p=0.80).
Although the x2 test suggested no hazard ratio modification,
inclusion of more strata and additional study estimates could
improve this assessment. Since some studies contributed tubercu-
losis cases to CD4-stratum estimates and to estimates across all
CD4 counts, the data used for the meta-analyses are not
independent. Although there was mixed evidence of publication
bias in this systematic review, the power to detect publication bias
increases as the number of studies included in meta-analyses
increases, and additional studies could strengthen the assessment
of publication bias for antiretroviral therapy’s preventive impact
on tuberculosis [60]. While heterogeneity for the meta-analysis
including all CD4 counts was calculated using I2 statistics and a
95% confidence interval, calculating I2 95% confidence intervals
for CD4 categories was not possible because of the limited number
of studies within CD4 strata. Although the meta-analyses included
antiretroviral therapy status and baseline CD4 count, other
analyses exploring community tuberculosis incidence, community
tuberculosis prevalence, participant history of tuberculosis, CD4
cell count recovery, and viral suppression might have provided
additional insight into antiretroviral therapy’s preventive impact
on tuberculosis if these variables had been collected systematically
in all studies. Finally, the validity of meta-analyses is subject to
proper analyses by investigators in included studies. Two of the
studies’ 95% confidence intervals [46,48] have asymmetry on the
logarithmic scale. These two studies were included in the meta-
analysis for all CD4 counts. In order to determine whether these
studies introduced bias into our results, we ran a sensitivity analysis
without them and found the results to be nearly identical (HR
0.35, 95% CI 0.28 to 0.44, with all studies, versus HR 0.38, 95%
CI 0.31 to 0.46, without [46] and [48]).
While there are many potential benefits to providing earlier
antiretroviral therapy, one risk of providing antiretroviral therapy
to people with CD4 counts above 350 cells/ml is that it may
compromise high adherence rates and potentially lead to
widespread antiretroviral resistance. While this is plausible, a
randomised trial has shown that adherence counselling facilitated
greater than 95% adherence to antiretroviral therapy in 79% of
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participants initiating antiretroviral therapy above 350 cells/ml and
74% of participants initiating antiretroviral therapy below 350
cells/ml [43]. Additionally, observational data indicate that the risk
of drug resistance is higher among people who started antiretro-
viral therapy below 350 cells/ml relative to those who started
antiretroviral therapy above 350 cells/ml [61]. There is also
concern that the risk of life-threatening antiretroviral therapy
toxicity could be higher among people with CD4 counts above
350 cells/ml; however, a randomised trial indicates that the risk of
life-threatening adverse events is similar in those initiating
antiretroviral therapy above 350 cells/ml and those initiating
antiretroviral therapy below 350 cells/ml (14% of participants in
each study arm experienced such an event, p=0.64) [43]. Results
from surveillance and future trials [54–56] are awaited to confirm
or refute these adherence and toxicity findings. Meanwhile, it is
important to continue to scale up antiretroviral therapy to achieve
universal access goals while also carefully conducting national
surveillance of antiretroviral toxicity [62] and antiretroviral
resistance [63].
While our analyses clearly show that antiretroviral therapy is
strongly associated with a reduction in tuberculosis incidence in
adults with HIV, its role in long-term tuberculosis elimination is
more complex [6–8,15]. Antiretroviral therapy’s effect on the
population incidence of tuberculosis depends on HIV prevalence
and the extent to which antiretroviral therapy (1) reduces HIV
transmission, (2) increases patient life expectancy, (3) reduces the
annual risk of tuberculosis, and (4) reduces subsequent tuberculosis
transmission. Dynamic models have suggested that antiretroviral
therapy reduces new HIV infections and that increasing antiret-
roviral therapy coverage in people living with HIV will lower the
population tuberculosis incidence [15]. Indeed, programmatic
data thus far indicate that antiretroviral therapy scale-up is
associated with reductions in tuberculosis incidence of 33% and
24% in high-burden Malawian and South African communities
[64,65]. Earlier antiretroviral therapy initiation could lead to a
more substantial reduction in population tuberculosis incidence
[15]. Expansion of antiretroviral therapy may also reduce HIV
incidence at the city [66,67], district [68,69], and national levels
[70,71], while decreasing tuberculosis mortality [72–74] and HIV-
related mortality [75–78].
Operationally, antiretroviral therapy’s impact on tuberculosis
control depends on (1) changes that facilitate access to HIV testing
Figure 2. Antiretroviral therapy use and hazard of tuberculosis by baseline CD4 count. The centres of the squares represent study
estimates, the centres of the quadrilaterals represent summary estimates, and the horizontal lines represent 95% confidence intervals. PY, person-
years; –, data not reported; *, study effect measure is an incidence rate ratio; {, data are from a randomised controlled trial.
doi:10.1371/journal.pmed.1001270.g002
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and linkage to care earlier in the course of HIV infection, (2) when
national guidelines and programme implementation allow people
to initiate antiretroviral therapy, (3) sustaining high adherence to
antiretroviral therapy, and (4) improving long-term retention rates
[16,17,79]. WHO recommends provider-initiated HIV testing and
counselling in all health facilities in generalised (i.e., antenatal HIV
prevalence $1%) epidemics [80]. Unfortunately, Demographic
and Health Surveys indicate that only approximately 11% of
people aged 15–49 y in generalised epidemics reported receiving
an HIV test in the previous year [81], and that many people with
HIV enrol onto antiretroviral therapy many years after HIV
seroconversion, after the development of tuberculosis and other
life-threatening illnesses, and after transmitting HIV to others [82].
A cluster-randomised trial recently found that community-based
HIV testing detects approximately four times as many people with
HIV as health-facility-based testing alone [83], and a 1-wk
community-based multi-disease campaign recently tested 47,311
Kenyans (87% of the target sexually active population 15–49 y of
age) and found that HIV-positive participants tested positive
earlier in the course of their HIV infection (median 541 cells/ml in
the campaign, [84]) than patients identified via health-facility-
based approaches [82]. In order to harness the lifespan, HIV
transmission, and tuberculosis prevention benefits of antiretroviral
therapy, HIV programmes in countries with a high HIV
prevalence need to expand HIV testing coverage and could
consider offering community-based HIV testing, with linkage to
antiretroviral therapy for those eligible, regularly to the general
public [85].
WHO’s Policy on HIV/TB Collaborative Activities currently
recommends the Three I’s for HIV/TB: intensified tuberculosis
case-finding [11], isoniazid preventive therapy [11], and infection
control [12] to prevent tuberculosis in people with HIV. WHO
infection control guidelines recommend administrative, manage-
rial, engineering, and personal respiratory methods to avoid
nosocomial tuberculosis transmission, such as logistical changes to
avoid patient congestion, and early identification and diagnosis of
tuberculosis patients in healthcare facilities, congregate settings,
and households [12]. Intensified tuberculosis case-finding involves
screening people with HIV for current cough, night sweats, fever,
and weight loss at every clinical encounter [11]. Those without any
of these symptoms have a very low probability of having
tuberculosis (98% negative predictive value in settings with a
tuberculosis prevalence of 5% [86]) and should be initiated on
isoniazid preventive therapy [11].
Isoniazid stops Mycobacterium tuberculosis replication during latent
infection and reduces tuberculosis incidence by 33% [87]. WHO
has recommended isoniazid preventive therapy for prevention of
tuberculosis in adults with HIV since 1993 [11,88,89]; however,
only a small fraction of the millions eligible received isoniazid
preventive therapy in 2010 [3]. Antiretroviral therapy causes viral
suppression and immune recovery, which reduces tuberculosis
incidence by 65% across all CD4 counts. Initiating antiretroviral
therapy as early as possible strengthens the WHO Three I’s for
HIV/TB strategy by building upon antiretroviral therapy’s
synergy with isoniazid preventive therapy. Indeed, observational
studies from South Africa [44,90], Brazil [45], and 16 other
countries [91] indicate that combined isoniazid preventive therapy
and antiretroviral therapy was superior to antiretroviral therapy or
isoniazid preventive therapy alone in reducing tuberculosis
incidence among adults with HIV. This finding was recently
confirmed through a cluster-randomised trial in Brazil, where
isoniazid preventive therapy reduced tuberculosis incidence
among Brazilians who remained in care and received antiretro-
viral therapy [92]. These data suggest that antiretroviral therapy
and isoniazid preventive therapy work by complementary
mechanisms and that simultaneous use substantially decreases
tuberculosis incidence in adults with HIV. Results from other
ongoing trials assessing the synergy between antiretroviral therapy
and isoniazid preventive therapy are eagerly awaited [54,56], and
ecological, operational, and clinical research on the impact of
scaling up antiretroviral therapy and the Three I’s for HIV/TB on
community and/or national tuberculosis incidence rates is needed
[93].
Table 4. Bias assessment for randomised controlled trials meeting inclusion criteria.
Study (Year)
Adequate
Sequence
Generation
Allocation
Concealment
Blinding of
Participants,
Personnel, and
Outcome Assessors
Incomplete
Outcome Data
Addressed
Free of
Selective
Reporting
Free of
Other Bias
Study
Score
Cohen et al.
[43] (2011)
1 1 0 1 1 1 83%
Samandari
et al. [49] (2011)
1 1 1 1 1 1 100%
Severe et al.
[51] (2010)
1 1 0 1 1 1 83%
A score of 0 indicates ‘‘no’’; a score of 1 indicates ‘‘yes’’.
doi:10.1371/journal.pmed.1001270.t004
Figure 3. Antiretroviral therapy use and pooled hazard ratios
of tuberculosis by baseline CD4 count. The circles represent
pooled estimates, and the vertical lines represent 95% confidence
intervals. The p-value for hazard ratio modification by baseline CD4
count category is 0.20. I2 values for the 0–200, 201–350, and greater
than 350 cells/ml categories are 0%, 58%, and 0%, respectively.
doi:10.1371/journal.pmed.1001270.g003
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In conclusion, antiretroviral therapy is a potentially safe, well-
tolerated, and HIV-transmission-interrupting intervention [43,94]
necessary to increase life expectancy in people with HIV [75–78].
There has been considerable debate on the optimal timing to start
antiretroviral therapy in asymptomatic adults with HIV. Published
results from ongoing randomised trials are expected in 2016 and
are eagerly awaited [54,55]. This review found that antiretroviral
therapy is strongly associated with a reduction in tuberculosis
incidence in adults with HIV across all CD4 cell counts. Our key
finding that antiretroviral therapy has a significant impact on
preventing tuberculosis in adults with CD4 counts above 350
cells/ml is consistent with studies from developed countries [95,96]
and will need to be considered by healthcare providers,
researchers, policymakers, and people living with HIV when
weighing the benefits and risks of initiating antiretroviral therapy
above 350 cells/ml.
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Editors’ Summary
Background. Tuberculosis—a contagious bacterial infec-
tion—is a global public-health problem. In 2010, 8.8 million
people developed active tuberculosis and 1.4 million people
died from the disease. Tuberculosis can be cured by taking
powerful antibiotics regularly for several months, and
between 1995 and 2010, 46 million people with tuberculosis
were successfully treated using DOTS—a directly observed
antibiotic regimen designed by the World Health Organiza-
tion (WHO). Now, though, the HIV epidemic is compromising
global tuberculosis control efforts. HIV-positive people are
very susceptible to tuberculosis because HIV, the virus that
causes AIDS, destroys the immune system cells (including
CD4 lymphocytes) that normally combat tuberculosis. In
2010, 1.1 million of the new (incident) cases of tuberculosis
were among the 34 million people living with HIV, and
350,000 people died of HIV-associated tuberculosis, making
tuberculosis the leading cause of death among HIV-positive
people. To tackle HIV-associated tuberculosis, which occurs
mainly in developing countries, WHO now recommends that
HIV and tuberculosis programs use collaborative approaches
such as the Three I’s for HIV/TB strategy—intensified
tuberculosis case-finding among HIV-positive people, isoni-
azid preventative therapy for HIV-positive people without
active tuberculosis, and (tuberculosis) infection control in
healthcare facilities, social settings, and households.
Why Was This Study Done? Despite progress in scaling
up the Three I’s for HIV/TB strategy, complementary
interventions are still needed to prevent tuberculosis in
HIV-positive people. Antiretroviral therapy (ART) lowers the
viral load of people infected with HIV and restores their
immune system function and could, therefore, prevent HIV-
associated tuberculosis, in addition to treating HIV infection.
WHO recommends ART for all HIV-positive adults with a CD4
count of less than 350 cells/ml of blood and for all HIV-
positive, tuberculosis-positive individuals irrespective of their
CD4 count. However, the evidence for ART’s preventative
impact on tuberculosis has not been systematically exam-
ined. Here, the researchers undertake a systematic review (a
search that uses predefined criteria to identify all the
research on a given topic) and a meta-analysis (a statistical
method for combining the results of studies) to investigate
the impact of ART initiated at various CD4 counts on the
development of tuberculosis in HIV-positive adults in
developing countries.
What Did the Researchers Do and Find? The researchers
found 11 studies that compared tuberculosis incidence by
ART status in HIV-infected adults over periods longer than six
months on average in developing countries and undertook
meta-analyses of these studies based on four categories of
CD4 count at ART initiation (less than 200 cells/ml, 200–350
cells/ml, greater than 350 cells/ml, and any CD4 count). For all
these categories, ART was strongly associated with a
reduction in the incidence of tuberculosis. For example,
the meta-analysis of the two studies that reported on
participants in whom ART was initiated at a CD4 count less
than 200 cells/ml yielded a hazard ratio (HR) of 0.16. That is,
study participants starting ART when their CD4 count was
below 200 cells/ml were about one-sixth as likely to develop
tuberculosis as participants not receiving ART. In the meta-
analysis of all 11 studies, study participants receiving ART
were about one-third as likely to develop tuberculosis as
study participants receiving no ART, irrespective of their CD4
count (HR 0.35). Importantly, the CD4 count at which ART
was initiated did not significantly alter the magnitude of
ART’s preventive effect on tuberculosis development.
What Do These Findings Mean? These findings suggest
that ART is strongly associated with a reduction in the
incidence of tuberculosis in HIV-positive adults in developing
countries, whatever the CD4 count at ART initiation. Because
most of the studies in this meta-analysis were observational,
these results do not show that ART causes a reduction in
tuberculosis incidence—other unknown factors shared by
the study participants who received ART may be responsible
for their lower tuberculosis incidence. Moreover, factors such
as variations in diagnostic methods among the studies
included in this meta-analysis may have affected the
accuracy of these findings. Nevertheless, the key finding
that ART is associated with a significant reduction in
tuberculosis cases among adults with CD4 counts greater
than 350 cells/ml should be considered by healthcare
providers, policymakers, and people living with HIV when
weighing the benefits and risks of early ART initiation. It also
suggests that early ART initiation (in combination with
expanded HIV testing) could be a key component of future
global and national strategies to control HIV-associated
tuberculosis.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001270.
N WHO provides information on all aspects of tuberculosis,
including information on tuberculosis and HIV, on the
Three I’s for HIV/TB, and on ART for tuberculosis
prevention (some information is in several languages)
N The TB/HIV Working Group is part of the Stop TB
Partnership, which is working toward tuberculosis elimi-
nation; patient stories about tuberculosis/HIV co-infection
are also available on their site
N The US Centers for Disease Control and Prevention has
information about tuberculosis and about tuberculosis and
HIV co-infection
N The US National Institute of Allergy and Infectious Diseases
also has detailed information on all aspects of tuberculosis
including HIV-associated tuberculosis
N Information is available from Avert, an international AIDS
charity, on HIV-related tuberculosis (in English and
Spanish), and from Aidsmap, a non-governmental organi-
zation, on HIV-associated tuberculosis
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